Sorry zedcorp - your logic is incorrect. All things being equal if the increase in Neuren's and Acadia's share price are both driven by the same event (positive Ph 3 results), then for every AU$1b additional market cap Acadia is worth Neuren should be worth at least AU$1b increase in market cap - and arguably (as 8horse has pointed out re larger market outside US) AU$3b or more.
It's very hard to come up with any sensible calculation that won't doesn't show every $100m in new revenue/profit Acadia makes long term from Trof will be matched by $300m+ for Neuren (and probably more - they won't have costs...). Long term for every $1 profit Acadia makes from Neuren's drugs Neuren should be making $5-$10.
Either Acadia's increase in market cap is hugely overpriced or Neuren's is hugely underpriced.
Share Price, page-421
-
- There are more pages in this discussion • 11,929 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.94 |
Change
-0.200(1.52%) |
Mkt cap ! $1.653B | |||
| Open | High | Low | Value | Volume |
| $13.03 | $13.06 | $12.75 | $7.500M | 581.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2300 | $12.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 2086 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |